Eli Lilly and Schrödinger Collaborate on AI-Driven Drug Discovery Platform

Eli Lilly has partnered with Schrödinger to integrate their LiveDesign drug development software with Lilly's TuneLab AI-based drug discovery platform. The collaboration aims to enhance the accuracy and efficiency of drug discovery through the use of artificial intelligence. This move reflects the growing trend of pharma companies embracing AI and machine learning technologies to accelerate the drug development process.